The Pfizer vaccine is highly effective in children between 5 and 11 years of age

Pfizer Inc. said its COVID-19 vaccine, developed in collaboration with Biontech Inc., has shown 90.7% efficacy against disease symptoms in children aged 5 to 11, according to a disclosure document published in the U.S. Food and Drug Administration. site web.

Next week external experts will meet on the Food and Drug Administration Advisory Committee on Vaccines and Related Biological Products to evaluate Pfizer and BioNTech’s application for emergency authorization of a pediatric COVID-19 vaccine.

If the committee votes to recommend approval and the Food and Drug Administration approves the vaccine, this could pave the way for Pfizer vaccine to be available for young children by early November.

The document was published on the site web of the FDA before the meeting scheduled for October 26. The efficacy result is based on a trial of about 2,250 children, according to the paper.

Pfizer and BioNTech applied for a permit for younger children in early October, after study data showed that a lighter dose of the vaccine increases antibodies to COVID-19. The pediatric dose of the Pfizer / Biontech vaccine is one third of the adult dose.

Read More About: Business News

Follow AsumeTech on

More From Category

More Stories Today

Leave a Reply